Vanda Pharmaceuticals | VNDA - Le Chiffre D'Affaires De Vente





Ventes Changement Date
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 73.74M 190.29M 2026-03
AstraZeneca USD 15.29B 213M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Halozyme Therapeutics USD 377M 74.76M 2026-03
Heron Therapeutics USD 40.59M 2.38M 2025-12
Insmed USD 305.96M 42.16M 2026-03
J&J USD 24.1B 500M 2026-03
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
Ligand Pharmaceuticals USD 51.72M 7.94M 2026-03
Merck USD 16.29B 110M 2026-03
Minerva Neurosciences USD 0 0 2024-09
Moderna USD 389M 289M 2026-03
Novartis USD 13.11B 750M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
PTC Therapeutics USD 273M 108.3M 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.24B 60M 2026-03
Takeda JPY 1.09T 100B 2026-03
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Veracyte USD 139.07M 1.53M 2026-03